Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) EBITDA Margin: 2009-2025

Historic EBITDA Margin for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to -11.33%.

  • Myriad Genetics' EBITDA Margin fell 195.00% to -11.33% in Q3 2025 from the same period last year, while for Sep 2025 it was -50.95%, marking a year-over-year decrease of 3689.00%. This contributed to the annual value of -14.74% for FY2024, which is 1943.00% up from last year.
  • Latest data reveals that Myriad Genetics reported EBITDA Margin of -11.33% as of Q3 2025, which was up 92.67% from -154.48% recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' EBITDA Margin ranged from a high of -9.38% in Q3 2024 and a low of -154.48% during Q2 2025.
  • Moreover, its 3-year median value for EBITDA Margin was -17.26% (2024), whereas its average is -34.33%.
  • Per our database at Business Quant, Myriad Genetics' EBITDA Margin soared by 6,230bps in 2021 and then plummeted by 13,722bps in 2025.
  • Over the past 5 years, Myriad Genetics' EBITDA Margin (Quarterly) stood at -26.80% in 2021, then tumbled by 256bps to -29.36% in 2022, then surged by 1,339bps to -15.97% in 2023, then tumbled by 255bps to -18.52% in 2024, then plummeted by 195bps to -11.33% in 2025.
  • Its last three reported values are -11.33% in Q3 2025, -154.48% for Q2 2025, and -14.80% during Q1 2025.